Fresenius Medical Care Midwest Dialysis, Llc is a medicare approved dialysis facility center in Milwaukee, Wisconsin and it has 17 dialysis stations. It is located in Milwaukee county at 4021 N 52nd St, Milwaukee, WI, 53216. You can reach out to the office of Fresenius Medical Care Midwest Dialysis, Llc at (414) 873-3600. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fresenius Medical Care Midwest Dialysis, Llc has the following ownership type - Profit. It was first certified by medicare in October, 1992. The medicare id for this facility is 522512 and it accepts patients under medicare ESRD program.
| Name | Fresenius Medical Care Midwest Dialysis, Llc |
|---|---|
| Location | 4021 N 52nd St, Milwaukee, Wisconsin |
| No. of Dialysis Stations | 17 |
| Medicare ID | 522512 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 4021 N 52nd St, Milwaukee, Wisconsin, 53216 | |
| (414) 873-3600 | |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
| NPI Number | 1457697237 |
| Organization Name | Fresenius Medical Care Midwest Capitol |
| Doing Business As | Fresenius Medical Care Midwest Dialysis, Llc |
| Address | 4021 N 52nd St Milwaukee, Wisconsin, 53216 |
| Phone Number | (414) 873-3600 |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
| NPI Number | 1528091287 |
| Organization Name | Midwest Dialysis Center - Capitol Branch |
| Doing Business As | Midwest Dialysis Center, Inc. |
| Address | 4021 N 52nd St Milwaukee, Wisconsin, 53216 |
| Phone Number | (414) 873-3600 |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 56% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 15% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 29% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 58% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 14% |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 58% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 18% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 24% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 60% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 12% |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 81% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 19% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 67% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 12% |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
| Dialysis patients with Hemoglobin data | 46 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 13 |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 103 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 989 |
| Percentage of adult patients getting regular hemodialysis at the center | 94 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fresenius Medical Care Midwest Dialysis, Llc with elevated calcium levels.
| Patients with hypercalcemia | 106 |
| Hypercalcemia patient months | 993 |
| Patients with Serumphosphor | 111 |
| Patients with Serumphosphor less than 3.5 mg/dL | 14 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 26 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 22 |
| Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 61 |
| Patient months included in arterial venous fistula and catheter summaries | 534 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 58 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 12 |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 82 |
| Hospitalization Rate in facility | 199.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 320.1 |
| Hospitalization Rate: Lower Confidence Limit | 127.9 |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
The rate of readmission show you whether patients who were being treated regularly at Fresenius Medical Care Midwest Dialysis, Llc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 19.7 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 26.9 |
| Readmission Rate: Lower Confidence Limit | 13.6 |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fresenius Medical Care Midwest Dialysis, Llc get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .17 (Better than Expected) |
| SIR: Upper Confidence Limit | .81 |
| SIR: Lower Confidence Limit | .01 |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fresenius Medical Care Midwest Dialysis, Llc's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 69 |
| Transfusion Rate in facility | 34.1 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 84.8 |
| Transfusion Rate: Lower Confidence Limit | 15.3 |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
The rate of mortality show you whether patients who were being treated regularly at Fresenius Medical Care Midwest Dialysis, Llc lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 369 |
| Mortality Rate in facility | 14 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 19.3 |
| Mortality Rate: Lower Confidence Limit | 9.8 |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago
Davita - Wisconsin Ave Location: 3801 W Wisconsin Ave, Milwaukee, Wisconsin, 53208 Phone: (414) 937-8240 |
Fresenius Medical Care Midwest South Location: 3267 S 16th St Suite 203, Milwaukee, Wisconsin, 53215 Phone: (414) 672-8230 |
Davita - Rivercenter Dr Location: 117 N Jefferson St, Milwaukee, Wisconsin, 53202 Phone: (414) 225-3740 |
FMC Dialysis - Milwaukee Location: 161 W Wisconsin Ave, Milwaukee, Wisconsin, 53203 Phone: (414) 224-7666 |
Fresenius Medical Care Midwest Dialysis, Llc Location: 4021 N 52nd St, Milwaukee, Wisconsin, 53216 Phone: (414) 873-3600 |
News Archive
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
› Verified 8 days ago